The Automated Syringe Dispenser is a radioisotope dispenser with a unique design for both clinical and research nuclear medicine. The dispenser allows for daily routine operations in a simple and reliable way without the need for consumable kits required by other syringe dispensers. The dispensing process can be simplified into a single step!
-Two stepping motors are used for positioning. An actuator accurately inserts the needle into the vial stopper. Another actuator draws the syringe plunger to the desired volume.
-A rotor turns the operating platform upside down during dose drawing and returns the platform to its initial position when the drawing is completed. This design prevents the liquid radioisotope from leaking when the needle is withdrawn form the vial stopper.
-The PLC programming is done using a touch screen that provides the ability to easily set the dose volume and the needle punch position.
-Dispensing a dose can be completed in 30 seconds!
-The system can accommodate a 10 to 10 ml tungsten vial shield
-The syringe volume is clearly visualized while in it syringe shield. An LED lighting system provides the viewing light source.
In May 2013, Ra-223 dichloride (Xofigo®) received marketing approval by the FDA as a treatment for patients with castration-resistant prostate cancer (CRPC), symptomatic bone metastases and no known visceral metastatic disease.
The use of radium-223 to treat metastatic bone cancer relies on the ability of alpha radiation from radium-223 and its short-lived decay products to kill cancer cells. Radium is preferentially absorbed by bone by virtue of its chemical similarity to calcium, with most radium-223 that is not taken up by the bone being cleared, primarily via the gut, and excreted. Although radium-223 and its decay products also emit beta and gamma radiation, over 95% of the decay energy is in the form of alpha radiation. Alpha radiation has very short range in tissues, around 2-10 cells, compared to beta or gamma radiation. This reduces damage to surrounding healthy tissues, producing an even more localized effect than the beta-emitter strontium-89, also used to treat bone cancer. Taking account of its preferential uptake by bone and the alpha particles’ short range, radium-223 is estimated to give targeted osteogenic cells a radiation dose at least 8 fold higher than other non-targeted tissues.
The recommended regimen is six treatments of 50 kBq/kg (1.3 uCi per kg), repeated at 4-week intervals.
With this exciting new development, Bayer, who produces Xofigo® has been heavily marketing the product to many cancer centers and clinics around the US. However many of these facilities do not have hot labs set up for the handling and use of radioactive materials like Ra-223. The Gollman Group has put together a quality, economical hot lab package to address the needs of facilities that are new to nuclear medicine and who wish to begin use of Xofigo®. If you are putting together a budget or already have plans to begin treatments and need to put together a hot lab, please contact The Gollman Group today.